Recently, IL-6 blockade was shown to inhibit mutant KRAS driven lung cancer [53], indeed several studies have shown increased IL-6 expression in lung tumors with mutant KRAS [54]—evidence of this relationship can also be observed from a parallel study on-going in our group (Supplementary Figure 4). This evidence concerns the gene IL6 and lung carcinoma.